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ABSTRACT 
The high incidence of obesity contributes to increased risk for chronic diseases and is an economic 
burden. In those with a BMI of ≥ 40 kg/m2 (severe obesity), or ≥ 35 kg/m2 with obesity related chronic 
diseases, bariatric surgery is the only available treatment that results in significant and sustained weight 
loss. However, bariatric surgery is expensive and has associated risks. An emerging treatment is the use of 
intragastric balloon which is becoming popular in America, as it’s non-surgical, helps with early satiety and 
is temporary. It is often used in conjunction with a comprehensive lifestyle modification program. A study 
to determine the safety and efficacy of the Spatz3 device was conducted at the Center for Clinical and 
Translational Science, Mayo Clinic in Rochester, Minnesota during 2017-2019. The purpose of this study 
was to evaluate the safety and effectiveness of the Spatz3 balloon in subjects with BMI between 30 and 40 
who had failed to achieve and maintain weight loss with a weight control program. Eligible 288 Subjects 
were studied in a randomized, controlled, multi-center study. The control group received individualized diet 
and exercise counseling for 32 weeks. The treatment group received individualized diet and exercise 
counseling plus the Spatz3 balloon for 32 weeks followed by counseling alone for 23 weeks. This paper 
offers the RD an insight into the rationale for the emerging non-surgical obesity treatment, history of intra-
gastric balloons, evidence of their efficacy, experiences of conducting a study and guidelines for 










The prevalence of adult obesity in the United States (US) has not met the target set up by Healthy People 
2020 to reduce obesity to 30.6% , according to the Centers for Disease Control and Prevention (CDC) 
summary.1,2 The CDC uses Body mass index (BMI) as a screening tool for obesity. BMI is calculated for 
adults by dividing weight in kilograms by the square of height in meters (kg/m2). The CDC categorizes 
normal body weight to be a BMI between 18.5 to ≤ 24.9 and overweight between 25 to 29.9. Obesity is 
defined as BMI of 30 or higher. Obesity is further divided into Class 1 (BMI of 30 to<35), Class 2 (BMI 
of 35 to <40) and Class 3 (BMI of 40 or higher) obesity, the latter is also referred to as extreme or severe 
obesity. Based on National Health and Nutrition Examination Survey (NHANES) and CDC data, in 2017-
2018 the age-adjusted prevalence of obesity among adults was 42.4%, compared to 30.5% during 1999-
2000 through 2017-2018.  Among younger adults age 20-39 it was 40.0%, among middle age adults age 
40-59 it was 44.8% and among older adults age 60 and over it was 42.8%. It was highest among adults 
age 40-59. There were no significant differences based on gender. Among ethnic groups it was lowest 
among non-Hispanic Asian adults (17.4%) in comparison to non-Hispanic white (42.2%), non-Hispanic 
black (49.6%), and Hispanic (44.8%) adults. Non-Hispanic black adults had the highest prevalence of 
obesity compared with all other race and Hispanic-origin groups. The age-adjusted prevalence of severe 
obesity in adults was 9.2% during 1999-2000 compared to 4.7% through 2017-2018. It was higher in 
women versus men. Overall, from 1999–2000 through 2017–2018, the prevalence of obesity and severe 
obesity increased, but the observed increase in the prevalence of obesity and severe obesity between 
2015–2016 and 2017–2018 was not significant. Socio economic factors play a role in the prevalence of 
obesity.  Men and women with less education had a higher obesity prevalence compared to those with 
college degrees.3 This pattern was seen among non –Hispanic white, non-Hispanic black, Hispanic 
women and non-Hispanic white men.  In contrast, in non-Hispanic Black men obesity increase was 
directly related to the education level. Education level did not factor in obesity prevalence among non-
Hispanic Asian women and men and Hispanic men.  Middle class income group showed higher 
prevalence than the lowest and highest groups in non-Hispanic white and Hispanic men. However, 
obesity prevalence was higher in the highest income group compared to lowest income group among non-
Hispanic black men. Highest income group in comparison to the middle and lowest income groups 
showed lower obesity prevalence among non-Hispanic white, non-Hispanic Asian and Hispanic women. 
Income did not have an impact on the prevalence of obesity among non-Hispanic black women.   
Hruby et al. suggest the ‘globesity’ epidemic we all live in is due to non-modifiable and modifiable risk 
factors.4 The authors stated heredity factors such as genetics and family history are beyond one’s control 
and therefore perhaps may be labelled as non-modifiable risk factors of obesity. They categorized 
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modifiable risk factors as those which generally can be changed by an individual.  These modifiable risk 
factors include: Individual behaviors such as diet (excess caloric intake, calorie/sugar dense foods, certain 
diseases such as Cushing’s disease, psychological conditions and drugs such as steroids), physical 
activity/sleep, socioeconomic risk factors such as income and education and environmental risk factors 
such as the built environment, food deserts, viruses, microbiota, Obesogens and obese social ties. The 
authors project that if the current trends continue, by 2030 ~38% of the global adult population will be 
overweight and another 20% will be obese. They predict that in the US over 85% of the adults will be 
overweight or obese by 2030.  
In comparison to the US, Minnesota has reported lower obesity rates except for 2002-2007 when they 
were very close to the national figures.5 However, from 2008 to 2017 the rate dropped below the national 
percentage. From 2000-2007 the rate increased from 17.4%to 26% representing an 8.6% increase. In 2018 
the obesity prevalence increased by 1.7 points from 2017 to 30.1% which is close to the national rate of 
30.9%. Although the change from 2017-2018 was not statistically significantly, the rate of obesity in 
Minnesota appears to have increased in the past decade.  
Data from the Medical Expenditure Panel Survey (MEPS), which is a comprehensive, nationally 
representative annual survey of the US civilian noninstitutionalized population reported in the US 
between 2001 (6.13%) and 2015 (7.19%) there was a 29% increase in national medical expenditures 
devoted to treatment of obesity related illnesses in adults.6 For the US as a whole, the average percentage 
of expenditures devoted to obesity between 2010 and 2015 was 9.21% for private payers including 
commercial health insurance, 6.86% for Medicare, 8.48% for Medicaid, and 4.74% for out-of-pocket 
payments by patients. The data for Medicare and Medicaid is of interest because it provides an idea of 
extent of the possible external obesity related costs that are a burden on the society as a whole. Spieker et 
al. suggest approximately 8.5% of annual Medicare spending is directed towards obesity-related health 
costs.7 In 2013 this cost represented $50 billion of the $585 billion Medicare spending. Since the obese 
Medicare beneficiaries are also more likely to have chronic medical comorbidities this results in increased 
treatment costs. The authors predict substantial Medicare costs ranging from $3.4 to $4.7 billion over 10 
years for 4% weight reduction among at-risk 60- to 64-year-old adults to Gross savings over 10 years of 
$7446 to $10,126 per capita with a 10% weight loss would be observed.  
Overweight and obesity are associated with increased risk of chronic diseases including type 2 diabetes, 
hypertension, certain types of cancer, joint problems and gallstones. An Pan et al. reported their findings 
of the relationship between body weight as a determinant of health-related quality of life (HRQoL) among 
2 cohorts of the US women.8 They followed 52,682 women age 46– 71 years in the Nurses’ Health Study 
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(in 1992–2000) and 52,587 women age 29–46 years in the Nurses’ Health Study II (in 1993–2001). Body 
weight (self-reported) and HRQoL (measured by the Medical Outcomes Study’s 36-Item Short Form 
Health Survey) data was collected every four years. Variables such as baseline age, ethnicity, menopausal 
status, and changes in comorbidities and lifestyle were factored in. Results indicated that over four years 
weight gain of 15 lbs. or more was associated with 2.05-point lower (95% confidence interval) physical 
component scores, whereas weight loss of 15 lbs. or more was associated with 0.89-point higher (95% 
confidence interval) physical component scores. Inverse relationship was found between weight change 
and physical dimensions as assessed by the questionnaire that included physical function, role limitations 
due to physical problems, bodily pain, general health, and vitality. However, small relationship was found 
between mental dimensions evaluated- social functioning, mental health, and role limitations due to 
emotional problems. It was concluded that weight gain prevention in general or weight loss in obese or 
overweight women will help improve HRQoL. Obesity is a risk factor for many chronic diseases and is an 
economic burden on our society and therefore health professionals should focus on its treatment. 
TREATMENT OPTIONS FOR PATIENTS WITH OBESITY 
In the US, current treatment options for obesity include weight management programs, pharmaceutical 
treatments, and bariatric surgeries (gastric bypass, sleeve gastrectomy and gastric banding). Irrespective 
of which treatment option is used, even small weight loss of 5-10% can improve the health profile by 
lowering blood pressure, cholesterol levels and blood glucose levels.9 
Weight loss management programs:  Weight loss management programs are those which include some 
combination of dietary change, behavior modification and/or increased physical activity. While most are 
successful in the short-term, sustaining weight loss requires continual adherence to these lifestyle 
changes. Greenberg et al. conducted The Dietary Intervention Randomized Controlled Trial, (DIRECT) to 
evaluate the effects of three diets in a two year study.10 Three hundred and twenty two moderately obese 
subjects (mean age 52 yrs., mean body-mass-index (BMI) 31 kg/m2 , 86% men)  were randomized to one 
of the three groups including low-fat, Mediterranean, or low-carbohydrate diets. Results indicated that 
overall compliance at month 24 was 85%: the highest compliance was in the low-fat group (90%) and the 
lowest compliance was in the low-carbohydrate (78%) group. Attrition was higher in women and 
smokers. Factors associated with attrition included higher baseline BMI and less success with weight loss 
at 6 months. Self-reported adherence to diet was greater on low-carbohydrate diet until month-6, but 
dropped overall from 81% at month-1 to 57% at month-24. Due to holiday eating significant decrease in 
diet compliance was reported but the subjects manage to bounce back to some extent. They concluded 
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that Initial 6-month weight loss of ≥ 5% was the main predictor of long-term success in weight loss and 
maintenance.  
Lenstra et al. conducted a meta-analysis of 27 (20 randomized controlled trials (RCT) and 7 observational 
studies) studies published between 2004-2015. They quantified adherence to weight loss interventions 
(education, self-monitoring, group based or individual exercise or diet interventions, peer support, and 
lifestyle interventions which included both diet and exercise) and identified those factors that promoted 
long-term adherence.11 They reported overall diet adherence rates of 60.5% across all of the treatment 
protocols. Contributing factors for high adherence rates were having a supervised attendance program, 
social support and diet intervention alone (versus exercise alone). The authors report higher adherence to 
diet alone versus exercise alone could be attributed to the self-reporting (poor recall/false information) of 
the diets by the subjects or due to the success with the restrictive diets.  Johns et al. conducted a 
systematic review and meta-analysis of 8 studies and a total of 1022 subjects to compare the weight loss 
of the combined behavioral weight management programs (BWMPs) that included diet, exercise and a 
clearly defined behavior strategy with diet and/or physical activity program alone.12 They included RCT 
of overweight (BMI ≥ 25) and obese (BMI ≥ 30) subjects or a BMI ≥ 23 in Asian populations age ≥ 18 
years and monitored weight for ≥ 12 months from baseline. Studies which used surgery or medications 
for weight loss or included other lifestyle changes such a smoking and alcohol cessation were excluded. 
The studies included weekly, monthly or bimonthly one on one counseling/education sessions conducted 
by qualified professionals. Dietary intervention of the studies selected included low calorie and low fat 
diets. The authors reported that the combined BWMPs group showed significantly greater weight loss at 
3-6 months and 12-18 months. For diet only and combined BWMP weight loss was similar in the short-
term but when diet and physical activity were combined weight loss was increased. They concluded that 
in the short-term and long-term combined BWMP programs are more successful in helping with weight 
loss than those based on physical activity alone. 
Pharmaceutical treatments:  According to the National Institutes of Health, National Heart, Lung, and 
Blood Institute (NIH, NHLBI), the existing pharmaceutical treatments for overweight and obesity work 
by creating a feeling of less hunger or early fullness and by aiding in decreasing the amount of fat 
absorbed from the foods consumed.14 Drugs that work by making one feel less hungry or full sooner 
include Belvig, Qsymia, Contrave, phentermine, benzphetamine, diethylpropion and phendimetrazine. 
Orlistat is the drug that reduces the amount of fat absorbed from the eaten food in the gut. Weight loss 
medications are prescribed in the US for adults with a BMI of 30 or greater (obese) or above 27 with 
weight related comorbidities such as hypertension or type 2 diabetes.14 The medications are recommended 
to be used in conjunction with lifestyle changes that encompass diet, exercise and behavior modification. 
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The impact of these medications is to provide an additional weight loss of 3-9% of their starting weight 
compared to lifestyle changes alone. 14 Table 1 gives an overview of the FDA approved weight loss 
medications.14 





Mechanism of action Common Side Effects 




Reduces the amount of fat the 
body absorbs from the food 
eaten 
Diarrhea, gas, leakage of 




MARKET in February 
2020 
Adults Acts on the serotonin 
receptors in the brain. Helps 
feel full after eating smaller 
amounts of food. 
Constipation, cough, 
dizziness, dry mouth, 




Adults A mix of two medications: 
phentermine, which curbs 
appetite, and topiramate, 
which is used to treat 
seizures/migraines. Curbs 
appetite and causes early 
satiety. 
Constipation, dizziness, 
dry mouth, taste changes, 
especially with 
carbonated beverages, 
tingling of your hands 
and feet, trouble sleeping 
CONTRAVE (Naltrexone-
bupropion) 
Adults A mix of two medications: 
naltrexone, which is used to 
treat alcohol and drug 
dependence, and bupropion, 
which is used to treat 
depression or help people 
quit smoking. Curbs appetite 
and causes early satiety. 
Constipation, diarrhea, 
dizziness, dry mouth, 
headache, increased 
blood pressure, increased 
heart rate, insomnia, liver 
damage, nausea, 
vomiting 
SAXENDA (Liraglutide)  
 
Available by injection only 
Adults At a lower dose under a 
different name, Victoza, 
FDA-approved to treat type 2 
diabetes. Curbs appetite and 
causes early satiety. 
Nausea, diarrhea, 
constipation, abdominal 







Mechanism of action Common Side Effects 
Other medications that curb 





Adults Increase chemicals in the 
brain to curb appetite and 
causes early satiety. 
 
Note: FDA-approved only 
for short-term use—up to 12 
weeks 
Dry mouth, constipation, 
difficulty sleeping, 
dizziness, feeling 
nervous, feeling restless, 
headache, raised blood 
pressure, raised pulse 
The impact of appetite suppressing medications was reviewed by Shyh et al.15 They found that Belvig, a 
serotonin enhancing drug, resulted in a 3-3.7% weight loss over a year of use. They reported headache, 
fatigue, nausea and dizziness side effects. Qsymia, is a combination of phentermine (appetite suppressant) 
and Topiramate (seizure medication). Side effects include paresthesia, dry mouth, constipation, dysgeusia, 
insomnia, dizziness and psychiatric problems and it is not recommended for use during pregnancy. 
Kang and Park reported Orlistat, a reversible lipase inhibitor which decreases fat absorption in the 
intestine, caused a mean weight loss of 2.6 kg at 6 month time point and 2.9 kg at 12 months in obese 
subjects.13 Use of this medication is limited by the bothersome gastrointestinal symptoms such as 
flatulence, diarrhea and liver damage.  
The side effects of the pharmaceutical treatments for obesity can be limiting for their long-term use. Due 
to the lack of long term research trials with these drugs, it is challenging to make a comparison of the 
benefits of these medications. Medical professionals must take into account the patient’s characteristics, 
metabolic profile, current medications, tolerance for side effects in order to use these effectively. 
Bariatric surgery: Fabricatore et al. have suggested for patients with a BMI of 40 or greater (extreme 
obesity), or above 35 with obesity related chronic diseases (high blood pressure, Type 2 diabetes or severe 
sleep apnea), surgical intervention (bariatric surgery) is the only available treatment that results in 
significant and sustained weight loss.9 According to the authors there is improved morbidity in obese 
patients treated with a standardized program using a preset selection criterion and multidisciplinary team 
approach. They also suggest bariatric surgery can potentially result in 25-30% weight reduction and 
significant improvements in hypertension, asthma, sleep apnea and diabetes. However the downside is 
surgery can be expensive and has associated risks, including infection, excessive bleeding, adverse 
reaction to anesthesia blood clots, lung problems, and leakage in the gut. Furthermore after surgery, 
problems such as bowel obstruction, dumping syndrome, gallstones, hernias, hypoglycemia, stomach 
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perforation, ulcers, vomiting and malnutrition may occur. The authors stated that the success of the 
outcome depends on the selection of a suitable procedure and skills of the surgeon. 
Roux-en-Y (RYGB) gastric bypass surgery involves creating a small proximal pouch ~30 cc in size from 
the stomach and connecting it directly to the small intestine. Ingested food goes into this small pouch and 
then directly into the small intestine. The food bypasses most of the stomach and section of the small 
intestine. Zingmond et al. reported that within 3-5 years of this surgery, 25% underwent follow-up 
procedures as a result of infections (8-20% rate).16 They also mentioned that between 1995-2004, among 
60,000 Medicare patients who underwent this procedure there was a fourfold increase in medical 
expenses (excluding surgery expense) three year post surgery versus three year prior to the procedure.  
Sleeve gastrectomy is typically performed laparoscopically and involves removal of 75% of the stomach 
creating a tube shaped gastric tube or ‘sleeve’. The procedure reduces the amount of ghrelin produced by 
the stomach and decreases the hunger feeling. Serious side effects of this procedure include leakage from 
the sleeve that can cause infection or abscess, pulmonary embolism or deep vein thrombosis, narrowing 
of the sleeve and bleeding.17 
The gastric banding procedure involves creating a small stomach pouch (about 30 cm) by placing a band 
in the upper part of the stomach. The net effect is to decrease the amount of food that can be consumed at 
one time. The band can be adjusted to help meet the individual weight goal needs, and can be removed. 
While less invasive and non-permanent as the other surgical procedures, banding has the disadvantages of 
displacement or damage of the band and tubing leakage requiring second surgery.17 
Flum et al. conducted a retrospective study to evaluate the risk of early mortality among Medicare 
beneficiaries undergoing bariatric surgeries.18 They included those who submitted claims for the 
following procedures for treating morbid obesity 1) gastric restrictive procedures without gastric bypass; 
vertical banding gastroplasty; 2) gastric restrictive procedures without gastric bypass; other than vertical-
banded gatroplasty; 3) gastric restrictive procedures with gastric bypass with short limbed (<100cm) 
RYGB; 4) gastric restrictive procedures with gastric bypass involving small intestine reconstruction to 
limit absorption. The authors included 16155 Medicare patients that underwent these procedures between 
1997 and 2002. Their results showed mortalities of 2% post 30 days and 4.6% post one year. The authors 
reported among the Medicare beneficiaries the risk of early death after bariatric surgery was considerably 
higher than previously reported and it was linked with advancing age, male sex and lower volume of 
surgeries performed by the surgeons. 
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INTRAGASTIC BALLOON TREATMENT 
As described above, bariatric procedures have become popular but are associated with significant 
morbidity and death, therefore less invasive medical procedures for morbid obesity have been developed. 
Recently, the FDA approved the Orbera intragastric balloon and the Reshape Duo intragastric balloon for 
treatment of obesity.19, 20 Intragastric balloons (IGB) placement is a weight-loss procedure that involves 
placing a saline filled silicone balloon in the stomach endoscopically. IGB are effective perhaps by one of 
the three mechanisms: reducing the stomach’s volume and thereby resulting in early satiety, changes in 
gastric emptying and changes in appetite regulating hormones such as ghrelin and leptin.21 IGB 
implantation along with a comprehensive lifestyle modification program which includes exercise, diet and 
behavior modification has resulted in successful weight loss. This weight loss can be maintained with 
behavior modification.  
HISTORY OF IGB 
Gleysteen has provided a comprehensive review of IGB treatments. IGB use in the US was first approved 
by the FDA in 1984.22 The first balloon was called the Garren-Edwards Gastric Bubble (GEGB) and was 
designed to be inserted endoscopically. It was a polyurethane cylindrical device filled with 200-220 ml 
air, with a hollow central channel and a self-sealing valve. The goal was to use this temporary device 
instead of bariatric surgery and remove it after 4 months. However, slow weight loss and complications 
were reported resulting in recall from the market in 1992. In 1987 the “Obesity and the Gastric Balloon; 
A Comprehensive Workshop” was held in Tarpon Springs, Florida. The objective of this workshop was to 
develop standards for the design of an ‘ideal’ gastric balloon. It was concluded that an ‘ideal’ balloon 
should be made of silicone elastomer, filled with saline, spherical shaped with a smooth surface, have a 
radiopaque marker, and an adjustable volume between 400-500 ml. IGB use was not recommended for 
patients who had had prior gastric surgery, and was for temporary use only. Congenital or acquired 
anomalies of the GI tract such as large hiatal hernia, atresia or stenosis, esophageal and or gastric varices 
are additional conditions for which the IGB are not recommended.23 Clinical application of the IGB 
included safe weight loss prior to surgical intervention and as an option for those who did not qualify for 
surgical treatment (BMI ≥40 or ≥35) but would benefit from losing weight and related lower morbidity. 
Those with BMI above 40 but below 50 and too old for surgery, qualified as well.  
After the Tarpon Springs conference, the BioEnterics Intragastric Balloon (BIB) was manufactured by 
BioEnterics Corporation in 1991 and was used in Europe, South America, the Middle East, and Asia. 
Later it was manufactured by other countries under the name Orbera Balloon. Endoscopic insertion of 
BIB has advantages as it is a quick and a safe procedure. Sallet at al reported results of 323 overweight 
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and obese patients who were treated with BIB along with a lifestyle program.24 The results at 6 months 
showed significant reductions in weight (15.2 ± 10.5 kg) and BMI (-5.3 ± 3.4). The authors report at 1- 
year follow-up, 85 patients had maintained > 90% of their BMI reduction. The side effects included 
nausea/vomiting (40% of the cases), epigastric pain (20% of the cases) and BIB had to be removed in 11 
patients (3.4% of the cases). Minor side effects reported included reflux esophagitis (12% of the cases) 
and symptomatic gastric stasis (9% of the cases). Balloon impaction was experienced by two patients and 
spontaneous deflation causing small-bowel obstruction in one patient.  
Since the introduction of BIB more companies have developed and used IGB’s outside the US. In 2007 
ReShape, Duo Integrated Dual Balloon System was manufactured in California but only used in Europe. 
In 2015 it was approved by FDA for use in the US. This balloon is unique as it is bi-lobed (shape of 
stomach) and filled with 900mL liquid. The Orbera and Reshape balloons are saline filled and implanted 
endoscopically in the inflated state.  The volume cannot be changed until it is deflated and removed 
endoscopically. Ponce at al conduced the REDUCE Pivotal Trial, a prospective double-blinded, 
multicenter RCT of 293 patients over 48 weeks in15 hospitals was conducted to study the safety and 
efficacy of this balloon and make comparisons of percent excess weight loss (% EWL).25 The mean BMI 
of the patients at the start of the study was 35.3 kg/m². It was found that patients in the DUO group 
(endoscopic balloon implantation plus supervised diet and exercise) experienced weight loss of 27.9 % 
EWL + 21.3 % EWL compared with 12.3 + 22.1% EWL in the DIET group (sham endoscopy plus diet 
and exercise).  In the REDUCE trial both the groups were studied for 24 weeks followed by balloon 
extraction from the DUO patients. The DIET group was given the option to have the balloon inserted at 
this point and then both groups were studied for another 24 weeks with continued counseling. Throughout 
the duration of 48 weeks improvements of co-morbidities and quality of life were recorded. Side effects 
of the balloon were experienced briefly for a week post implantation but were manageable. The balloon 
was removed prematurely in 24 patients but incidents of death, intestinal obstruction, gastric perforation 
or balloon migration were not found. Side effects such as gastric ulceration in 35% of the cases and 
balloon deflation in 6% were reported in this trial. 
The Heliosphere BAG designed by Helioscopie Medical Implants Company in France, has been the 
longest (since 2004) non-US manufactured device in use. This device weighs 30 g and differs from the 
design developed at the Tarpon Springs conference as it is filled with air and not saline. It is called a bag 
because it is made out of an internal polyurethane envelope filled with air and the outside is a silicon 
pouch. Mion at el studied 32 patients with mean BMI of 35 to evaluate the tolerance and weight loss 
using this air filled balloon.26 In this study the balloon was inserted under general anesthesia and then 
inflated with 800 ml air. From the authors findings significant weight loss was reported at 1, 2 and 4 
12 
months. At 1 month it was 6 kg followed by 7 and 10 kg at months 2 and 4. They removed the balloon 
after 4 months but monitored the patients up to a year. In 3 patients they had to remove the balloon 
prematurely. The authors reported at 12 months- mean weight loss of 7kg and 9 out of the 26 remaining 
patients had > 10% weight loss: satisfaction with the procedure was 87%. They concluded that the air-
filled IGB was safe and its effect on weight loss was comparable to other balloons. Compared to the 
silicon balloons this bag showed fewer side effects such as nausea, vomiting and discomfort. There were, 
however, reports of difficulties in retrieving the bag during extraction at 6 months in several patients 
requiring surgical removal. In 8% of the patients spontaneous deflation and movement of the bag to the 
intestinal tract before 6 months occurred. 
Another design for an air balloon called the Intragastric Prosthesis Endogast was developed in France by 
Districlass Medical SA. This oval shaped balloon made out of polyurethane had an attached 15 cm long 
polyutherane catheter which extended through the gastric and abdominal wall into a subcutaneous pocket 
which was surgically made near the costal margin. The end of the catheter had a stainless steel chamber 
with self-sealing rubber membrane to allow external injection of air. The purpose of this design was to 
allow outside control of air volume in the balloon – a starting capacity of 300 mL of air was used. The 
advantages of this design are that it could be planted for a longer time (more than a year) in comparison to 
floating balloons however, it has been associated with risk of infection. Gaggiotti et al. conducted a 
multicenter prospective clinical survey to evaluate the effect of Adjustable Totally Implantable 
Intragastric Prosthesis (ATIIP) – Endogast for treating morbid obesity study.27 Fifty seven  morbidly 
obese subjects (mean BMI of 49) showed weight loss of 12.2 kg after a year of insertion. Subcutaneous 
infection rate was 12%. One patient had complications with local infection and therefore the prosthesis 
was removed. This design may be helpful in preparing patients for a later bariatric surgery. From the 
authors findings they concluded that ATIIP is feasible, reproducible, safe, has low risk of complications 
and helps with weight loss. They indicate the use of this device for the morbidly obese patients > 60 years 
old and the super obese (BMI> 50). 
Two other systems, the Semi-stationary Antral Balloon (SAB) and Silimed Gastric Balloon (SGB) were 
unique designs developed in Brazil in 2006. These are made of silicon and filled with saline with added 
contrast medium and methylene blue. SAB has a unique pear-shape at the distal end, is placed in the 
stomach antrum and attached distally to a 30 cm long silicone duodenal stem with a metallic tip. The 
purpose of this device is to promote satiety by intermittently blocking the pylorus, delaying gastric 
emptying and activating stomach and small intestinal receptors. The SGB balloon is circular in shape.  
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EFFECTIVENESS OF IGB 
Courcoulas et al. conducted a 12 month multicenter, prospective, randomized, open label clinical trial of 
255 adults.28 Subjects had a BMI of 30-40, history of obesity for at least 2 years and poor success with 
traditional weight loss programs such as supervised diet, exercise and behavior modification programs. 
The study was conducted under the Food and Drug Administration (FDA) Investigational Device 
Exemption protocol and the goal was to research the safety and effectiveness of the IGB for weight loss in 
the US adults. Subjects were randomized to the intervention group (endoscopic placement of IGB and 
lifestyle modifications) or the control group (lifestyle modifications alone).The lifestyle modification 
program included a low calorie diet of 1000-1500 calories, food and exercise diary, and recommended 
exercise and behavioral changes. The modification program was implemented for 12 months in the 
control group; after 6 months, the intervention group had the balloon removed but continued lifestyle 
changes for another 6 months. The study involved 21 visits for screening and follow-up over the 12-
months. At 6 months, weight loss (of total body weight) was -3.3% (-3.2 kg) versus -10.2% (-9.9 kg); at 9 
months -3.4% (-3.2 kg) versus –9.1% (8.8 kg); and at 12 months -3.1% (2.9 kg) versus -7.6% (-7.4 kg) in 
the control versus the intervention group, respectively. At 9 months mean percent loss of weight in excess 
of the ideal body weight (IBW) was 9.7% and 26.5% in the control and intervention group, respectively. 
IBW is defined as the weight that is believed to be optimum for a person.29 In the treatment group 45.6% 
of the subjects showed at least 15% loss of weight in excess of IBW which was greater than the control 
group. The balloon implantation group reported symptoms of nausea, vomiting, and abdominal pain. Of 
these patients, 18.8% had their device removed prematurely due to these side effects or personal choice. 
In 3.1% of the subjects at the time of balloon removal some stomach changes (infection, outlet 
obstruction, perforation, and gastritis) were noticed. Based on the results the authors concluded that 
complementary treatment with the IGB produces modest, short-term (3 and 6 months post balloon 
extraction) weight loss which is greater than lifestyle modifications alone.  
 
SPATZ BALLOON 
Spatz balloons are approved for use in Europe and are widely used for obesity reduction. In the US they 
are currently under clinical trials investigation by FDA. This balloon is an improvement over the previous 
balloons as it can be implanted for a longer time period, about one year, the volume can be adjusted to 
match the desired weight change and it does not move post implantation.30 A unique feature of this 
balloon is the extractable thin filling catheter which makes it possible to adjust volume externally to suit 
the individualized needs of weight loss and tolerability. The Spatz3 device is the only IGB that meets all 
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the standards defined at the Tarpon Springs conference. This balloon has a smooth surface, is filled with 
saline, has an adjustable size and radio-opaque markers. 
A study to determine the safety and efficacy of the Spatz3 device was conducted at the Center for Clinical 
and Translational Science (CCaTS), Mayo Clinic in Rochester, Minnesota during 2017-2019. As a 
registered dietitian in this unit, I was involved in the development and implementation of the study. After 
presenting the study design I will discuss my role in developing and execution of the comprehensive 
individualized lifestyle modification program for this study. 
STUDY TITLE  
A randomized, controlled, multicenter study comparing the Spatz3 Adjustable Balloon System plus 
diet and exercise to diet and exercise alone 
HYPOTHESIS 
Patients who receive the Spatz3 balloon for 8 months will lose significantly more weight than those 
treated with diet and exercise alone. 
FUNDING 
Funding source is commercial/industry entity - Spatz FGIA, Inc. 
OVERSIGHT 
The study conducted at CCaTS research unit was approved and manage by the Mayo Clinic Institutional 
Review Board (IRB) and followed all clinical trial safety and privacy regulations. Prior to being enrolled 
in the clinical study the subjects were informed of the nature, scope and possible consequences of the 
study, in an understandable manner, as per IRB guidelines. The original signed consent form was kept by 
the investigator and a copy was given to the subject. The subjects were free to withdraw from the study at 
any point. The Iowa State University IRB was not required to approve this study as determined by their 
assessment form. The study had been completed and closed for enrollment prior to submission of this 
Creative Component, and no part of the study was conducted by ISU faculty or students after the initial 
IRB review. 
DESIGN 
The purpose of this study was to evaluate the safety and effectiveness of the Spatz3 balloon in subjects 
with BMI between 30 and 40 who had failed to achieve and maintain weight loss with a weight control 
program. Subjects were studied in a randomized, controlled, multi-center study. The control group 
received individualized diet and exercise counseling for 32 weeks. The treatment group received 
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individualized diet and exercise counseling plus the Spatz3 balloon for 32 weeks followed by counseling 
alone for 23 weeks. 282 eligible subjects were randomized to treatment (188) or control (94) arm. All 
treatment group subjects underwent endoscopy and only those without endoscopy contraindications had 
Spatz3 balloon implanted for 32 weeks. Subjects in both groups followed a 1000-1200 kcal/day weight 
loss diet during the study. The personnel weighing the subjects were blinded to the group randomization. 
At 18 ± 4 weeks, treatment arm subjects were evaluated, and those that met the criteria underwent an 
adjustment procedure to increase the balloon volume to achieve extra weight loss. The local physician 
was approved to make an adjustment to the balloon volume at any time if the patient had symptoms of 
continued nausea, vomiting, uncontrolled gastro-esophageal reflux or abdominal pain in spite of 
conservative symptomatic treatment. Volume adjustment guidelines are outlined in table 2. 
Table 2: Volume Adjustment Guidelines 
For intolerance that continued more than 7-10 days beyond the first 5 days after implantation or that 
occurred at any time during the 8 months, the investigator may decide to: 
● Remove 150 ml from balloon (when initial volume is 450-550ml) 
● Remove 100 ml from balloon (when initial volume is 400ml) 
● The final volume could not be reduced below 300ml.  If medications and balloon volume down 
adjustment did not alleviate the intolerance, the balloon had to be extracted. 
 
At the end of the 32-week treatment period the control group completed the study and the treatment group 
underwent balloon removal followed by a 24-week follow up. The balloon implantation and adjustment 
procedures were done endoscopically under sedation. Figure 1 below gives an overview of the study 







Figure 1. Overview of the study timeline 
 
SETTING 
It was a multicenter trial  with potentially 10 centers - Mayo Clinic, Rochester; Endoscopic Micro 
Surgery, Maryland; Surgical Associates of Louisiana, Metairie; Ohio State University Medical Center; 
Columbus; University of Chicago Med Center, Chicago; NY VA Medical Center, NY; Brigham & 
Women’s Hospital, Boston. Enrollment at each site was limited to 65 subjects. Study inclusion and 
exclusion criteria are outlined in Table 3 below. 
Table 3: Study inclusion and exclusion criteria 
INCLUSION CRITERIA 
● Age 22-65. 
● BMI ≥ 30 and <40. 
● Willingness to comply with the substantial lifelong dietary restrictions required by the procedure. 
● Obesity (BMI ≥ 30) or at least 2 years. 
● Failure with non-surgical weight loss methods. 
● Willingness to follow protocol requirements, including signed informed consent, routine follow-
up schedule, completing laboratory tests, completing diet counseling. 
● Residing within a reasonable distance from the investigator’s office and able to travel to the 
investigator to complete all routine follow-up visits. 
● Ability to give informed consent. 
● Adequate birth control methods by women of childbearing potential (i.e., not post-menopausal or 
surgically sterilized). Acceptable birth control methods are limited to hormonal contraceptives 
(oral, flexible vaginal ring, skin patch, injection), diaphragms, IUDs, condoms with or without 
spermicide, and voluntary abstinence. Should a treatment arm subject become pregnant during the 
implantation period, the balloon will be extracted during the second trimester-the timing of which 





● Gastrointestinal surgeries with sequelae, bariatric surgery, surgery involving esophagus, stomach, 
hiatal hernia. 
● Inflammatory disease or bleeding condition of the gastrointestinal tract (GIT). 
● Gastric mass. 
● Hiatal Hernia >2cm or severe intractable gastro-esophageal reflux symptoms. 
● Structural abnormality of the esophagus or pharynx that may pose difficulty and risk with passage 
or removal of the balloon. 
● Severe coagulopathy. 
● Insulin dependent diabetes or requiring insulin treatment in the following 12 months. 
● Health conditions that increase risk of endoscopy. 
● Chronic abdominal pain and motility disorders of GIT. 
● Hepatic insufficiency or cirrhosis, H. Pylori and cardiopulmonary diseases. 
● Serious or uncontrolled psychiatric illness or disorder.  
● Alcoholism or drug addiction. 
● Unwillingness to participate in an established medically supervised diet and behavior 
modification program, with routine medical follow-up. 
● Medication use: aspirin, anti-inflammatory agents, anticoagulants, gastric irritants, those that 
affect serotonin levels, anti-seizure and antiarrhythmic medications, corticosteroids, 
immunosuppressant, diet pills and narcotics. 
● Unwillingness to take proton pump inhibitor medication for the duration of the implant. 
● Allergies to materials contained in the balloon system. 
● Pregnancy or breastfeeding. 
● Prior use of intra-gastric devices or prior weight loss programs that could affect weight loss in the 
past 6 months. 
● Symptomatic congestive heart failure, cardiac arrhythmias or unstable coronary disease. 
● Respiratory disease such as chronic obstructive pulmonary disease (COPD), pneumonia or 
cancer. 
● Autoimmune connective tissue disorder e.g. lupus, erythematous, scleroderma) or 
immunocompromised. 
● Life expectancy less than 1 year or severe medical condition as decided by the investigator due to 
increased risk profile. 
● Genetic or hormonal cause for obesity such as hypothyroidism or Prader-Willi Syndrome. 
● Eating disorders: night eating disorder (NES), bulimia, binge eating disorder, or compulsive 
eating. 
● Endocrine disorders affecting weight. 
 
 
COMPREHENSIVE INDIVIDUALIZED LIFESTYLE MODIFICATION PROGRAM FOR THE 
STUDY 
TRAINING OF THE REGISTERED DIETITIANS 
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The funding company conducted a site visit in July of 2016 during which they educated me and my 
colleague, also a registered dietitian, regarding the balloon environment, purpose of the FDA pivotal trial, 
role of dietitian, subject selection and symptom management and understanding of the balloon. The 
training was very important because this was the first balloon study to be conducted at our research unit. 
The company conducted 2-3 conference calls in fall of 2016 to reiterate the important points, evaluate the 
understanding of the initial education conducted at the site visit and to address concerns. Dietitian Intake 
Form (table 5) for screening, dietitian form for weekly and monthly visits (Appendix A) and the physical 
activity questionnaire (Appendix B) were finalized. Handouts used for nutrition and exercise education 
(Appendix C) were standardized by the company. All these forms were monitored and audited by the 
company. 
The educational slides used by the company are confidential and therefore they cannot be shared. 
Following is an outline of the diet.  
THE MULTI-LEVEL DIET 
 
The subjects were educated on a four level diet progression as outlined below in Table 4. This diet 
progression represents the average pace of advancement of diet.  
 
Table 4. Multi level diet post balloon implantation 
Stage Duration Details 
1-Clear liquid 24 hours post procedure Water, tea, clear juices, Jell-O, 
broth 
2- Liquids Days 2-4 (May last 7 days) Dairy products: Cottage cheese, 
yogurt, pudding, milk, etc. 
3- Soft foods Days 5-10 (May last 15 days) Tuna, soft boiled egg, cooked 
chicken/fish, cooked and peeled 
vegetables, mashed potatoes,  
etc. 
4- Normal diet After 10-14 days Foods in accordance with the 





STAGE 1-Clear Liquids. Day 1 
1. Begin drinking water and clear liquids as quickly as possible to avoid dehydration. 
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2. Drinking should advance gradually with small sips of water with a teaspoon progressing to 
1/4thcup water and then half glass of water every hour. 
3. Liquids should be spread evenly throughout the day. 
 
STAGE 2- Liquid diet. Day 2-4 
1. Advance only if there is good tolerance and no feeling of nausea or vomiting. 
2. Gradually start tasting the following: natural yogurt 3% with no added fruit or sugar, soft white 
cheese, cottage cheese, milk, etc. 
3. Patients should drink at least 1 liter of liquids (preferably water) at this stage. 
a. Temporary constipation is very common during the first week after the procedure. 
i. Rationale includes consumption of less food, fiber and liquid intake accompanied 
by lack of physical activity. 
b. On day 4 patients should add on a daily chewable multivitamin and Probiotic. 
 
STAGE 3- Soft Foods. Day 5-10 
1. Patients should only proceed if Stage 2 is well tolerated. 
2. Gradually add foods with soft and easily mashed texture. 
3. Cottage cheese, tahini, avocado, semolina or corn flour (milk or water base). 
4. White bread without crust can be introduced into the diet.  
5. Protein should be the main macronutrient at this stage to help replenish muscle breakdown. 
6. Protein dishes such as soft boiled egg, tuna, cooked chicken and fish should be emphasized. 
7. Protein powders should be added if protein intake is low. 
8. Cooked and peeled fruits and vegetables such as apples, pears, zucchini, carrots, squash and 
sweet potatoes should be added carefully. 
9. Drinking 1.-2 L of water throughout the day is important. 
10. Continue with Probiotic and Multivitamin. 
 
STAGE 4: A gradual return to a normal diet. Days 10-14. 
1. Patients should only proceed if stage 3 is well tolerated. 
2. Gradually reintroduce lean beef, chicken, turkey, boiled rice, whole wheat bread and rye. 
3. Fresh fruits and vegetables can be gradually introduced at this stage. 
4. Drinking 1.5-2 liters of water throughout the day is encourage. 
5. Continue with Probiotic and multivitamin. 
 
Protein Intake: 
● 0.8 gm. /kg body weight protein is recommended. 
● There may be new intolerances to meat.  




● Start multivitamin and Probiotics on day 4. 
● Use Ensure and other supplemental protein drinks if diet is inadequate. 
 
Common Side Effects right after Balloon Insertion: 
● Side effects start 0-6 hrs. post implant. 
● Last for the first 3-4 days. 
● May be challenging to get enough fluids the first 1-2 days. 
● Make patients aware that side effects such as nausea, vomiting, abdominal pain/spasms, 
heartburn, fatigue and weakness are expected in spite of the medications given to relieve them. 
These usually subside within 3-4 days. 
 
Other Side Effects: 
● These may appear days/weeks after procedure. 
● Burping/Belching 
o Gastric discomfort triggers frequent saliva swallowing with air. 
o Gastric odor may be a problem. 
● Bloating 
o Gas builds up in the stomach and intestines. 
● Flatulence 
o Gas builds up in the colon due to fermentation of undigested food. 
 
GENERAL GUIDELINES FOR THE SUBJECT FOR THE FIRST 2-3 WEEKS. 
● Eat slowly and with little distractions such as television and smartphone as much as possible.  
● Develop a routine for eating meals. 
● Eat a variety of foods to minimize dietary deficiencies. 
● Introduce foods slowly and by trial and error learn about their tolerance. Tolerance to foods may 
change after balloon implantation. 
● Plan ahead for events such as eating out in restaurants and on special occasions. 
● Limit intake of refined sugars and unhealthy fats. 
● Moderate exercise including walking 150-200 minutes per week may be started. 




SET-UP OF THE STUDY FOR THE RESEARCH UNIT 
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Each new study is set up in the CRU (Clinical Research Unit) Tools (software program developed by our 
information technology team) by the multidisciplinary team consisting of nurses, dietitians, pharmacy, lab 
and the study team study coordinator/investigator. This study set-up and scheduling system is very 
unique. The set up includes adding a template for the visits (screen, week 1 visit, week 2 visit, monthly 
follow up) with the dietitian, nurse and/or the study coordinator; verification of consent form; details of 
the activities to be covered; order in which they meet with the subject; anthropometrics and tests 
conducted; documents to be used etc. After this the study is activated and ready for enrollment. The visits 
are scheduled in the system using a code for example ‘screen’ to facilitate the schedulers to add a patient 
for the screen visit at our unit. Automatically this subject’s screen visit is added on our nutrition calendar. 
This process gives us an opportunity to prepare our nutrition guidelines for the study and sign off in the 
system when we are ready for the study. For this specific study it was important that my colleague and I  
had a good grasp of the study which we did after the training sessions with the company.  We both were 
in agreement with the counselling strategies and we drafted a curriculum of the nutrition topic for follow-
up visits. After the study was active revised the template of the visits as needed. The history of the study 
including the protocol, consent form, study staff, budget, education materials, approvals, modifications 
and incident reporting may be found in CRU Tools.  
ONE-ON-ONE VISIT WITH THE SUBJECTS 
SCREENING VISIT 
Our first visit with the subjects was at the screening visit (> 30 days prior to implantation) and it included 
physical exam, labs, vitals, consent form signature, psychological evaluation and dietitian visit. We met 
with the subjects for an hour long appointment during which we collected information for the Dietitian 
Intake Form. The details of the information collected for this form are outlined in the table 5 below. The 
objective of this form was to learn about the subject as a whole-their environment, support system, past 
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efforts at weight loss, personal goals, hurdles and their habitual food intake. It gave an insight into their 
current weight, readiness to make changes, short term goal weight, calorie and protein needs etc. 
Table 5 : Dietitian Intake Form 
● Do you Smoke? 
● Do you use Oral contraceptives? 
● Do you add Nutritional additives to foods? 
● Do you have any life stressors  
● Do you take laxatives? 
● Do you take enemas?    
● Do you take diuretics?   
● Do you have vomiting episodes more than once a year?   
● Do you have a Physical Exercise Routine? Is it less than or more than once a week?     
● Any Past Weight Loss Attempts? Were they self-imposed or via a commercial diet center? 
● What was your lowest weight since adulthood? How long were you able to maintain it?   
● What was your highest weight since adulthood?         
● Were you ever underweight as an adult?      
● Do you ever binge eat?         
● Do you feel that you do not have control over your eating?     
● Have you ever self-induced vomiting?        
● Have you ever fasted in order to lose weight?       
● Have you used enemas, laxatives, diuretics or diet pills in order to lose weight?  
● Describe any other difficulties you may have other than weight issues?  
● Have you been under psychiatric or psychological care with respect to your weight issue?       
● What help do you want to receive with this therapy and counseling?  
● What has to happen in order for this therapy to succeed in yielding weight loss?  
● Is there anything else that you think is important for us to know about you which hasn't been covered 
in this questionnaire?  
● Share your current diet for a typical day starting with the first thing you eat or drink. 





o Milk/milk Products 
o Meat/Chicken/Fish 
o Sweets 
o Water, tea and coffee 




Measurements and Nutritional Assessments 
 Actual Ideal 
Weight    
BMI   
Height  N/A 
Excess Weight  N/A 
 
Nutritional Requirements 
Calories: Calculate weight loss calories by incorporating ~500-1200 Kcals/day deficit.  
Basal_________ Kcals + Activity = _______ Total Kcals -________ deficit =________weight loss 
kcals/day. NOTE IF DIFFERENT __________  
 
● Protein Needs:  ____ kg weight (current wt.) X 0.8 kg=_____ gm/day  
Expectations 
● Short-term Goals:  
 
● Goal Weight : 
 
Also, we educated subjects on diet and exercise to follow during the study. The control group followed 
the diet and exercise progression to mimic the treatment group.  Diet started on the day of randomization 
or post procedure depending on the group. Exercise started on week 3. The subjects were encourage to 
avoid planning too many activities for the first few days after the procedure due to the possibility of low 
energy level. In addition, they were instructed to be prepared with groceries needed for the first few days. 
Outlined below are the dietary instructions the dietitian gave to the subjects.  
DIETARY INSTRUCTIONS 
Stage A: Liquid diet 1-7 days after Balloon procedure 
Day 1: one glass of water every hour (half to quarter cup at a time). Later in the day add weak tea. 
Day 2: You can add broth (chicken cooked with vegetables and oil-filtered) or pure juices (i.e., grape, 
apple, pear etc.). 
Day 3: You can add milk, coffee, fruit and vegetable juices filtered, jelly, liquid yogurts without pieces of 
fruit. No carbonated beverages. 
Important rules for this stage: 
● In the first few days, be sure to drink the above recommended liquids at room temperature-not too 
cold or too hot. 
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● Do not drink more than a quarter to half cup at a time. 
● Make sure to drink slowly and in small sips to avoid swallowing air while drinking (do not drink 
with straw). 
● Do not drink carbonated beverages. 
● Make sure to drink 10 cups of fluids throughout the day. 
● To get enough calories and protein it’s recommended to keep most of the drinking based on dairy 
products. 
● Make sure to add one tablespoon a day of good fats-like olive oil, canola oil, tahini or avocado to 
provide essential fatty acids and prevent complications. 
Please note: From day 4 onwards the dietary advancement depends on each person and may be slower or 
faster for you than what is presented. 
Table 6: Example of daily routine Days 3-7: 
08:00: 1C of coffee with ½ C milk, ½ C water 15:00: ½ C yogurt or white cheese 
09:00: ½ C of yogurt 16:00: 1 glass water 
10:00: clear juice 17:00: Clear juice 
11:00: 1 glass water 
 
18:00: 1 C broth with 1t olive oil 
12:00: 1C broth (chicken cooked with vegetables 
and oil, filtered. Add 1t olive oil 
19:00: 1 glass water 
13:00: 1 glass water 20:00: 3 t cottage cheese 
14:00: 1C coffee with ½ C milk 21:00 1 glass water 
 
Stage B: Blender/soft diet days 7-14: 
In addition to foods you drank or ate at Stage A, gradually add the following foods in the order they are 
written: 
● Soft white cheese or cottage cheese, tahini or hummus (low fat), avocado (mashed), oatmeal 
based on rice flour or corn flour. 
● Eggs: After 11-12 days, soft or hard-boiled egg mashed in a blender, Moss tuna (tuna in a blender 
with olive oil, tahini, avocado or light mayonnaise). 
● Purees of vegetables and fruits without seeds, cooked and peeled and ground (zucchini, squash, 
carrot, banana, apple, pear) Peeled tomato, crushed in a blender ( or mix with a teaspoon of olive 
oil – can help with constipation if it is a problem) 
●  Fish/chicken (no skin)/turkey-After 8-9 days, ground in a blender. 
Important rules for this Stage: 
1. The progress at this stage should be gradual-a new food every day. If after adding a certain 
food you do not feel well (pain, bloating, etc.) stop it and try it again after a few more days. 
2. It is recommended to start with 2 T of food several times a day and to gradually increase the 
amount according to your personal feeling. 
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3. Keep chewing slowly. Each meal should take at least 20-30 minutes. 
4. Check how you feel during meal time and stop eating after a few tablespoons according to 
how you feel. 
5. Be sure to drink 8-10 glasses of fluids throughout the day. Helps to prevent constipation. 
6. Continue to take on multivitamin daily. 
7. It is important to eat a small meal every 2-4 hours. Do not get hungry before meals to avoid 
eating too fast or too much. 
8. Make sure to keep proper eating habits: eating and sitting at the table without doing other 
activities such as watching television. 
9. At this stage it is important to avoid drinking sweetened drinks or high fat foods that can 
cause obesity or prevent a decrease in weight. 
10. It is important to include protein in every meal. 
 
Table 7: Example of daily routine Days 7-14 
07:00: 1 C coffee with ½ C milk. No sugar 15:00: ½ C orange juice or grapefruit juice or 
vegetable juice; 1 glass water. 
08:00: Milk based porridge or 2-3 T white cheese 
with boiled egg and tomato; 1 glass water 
17:00: 2 T of tuna or boiled eggs or 2 T of white 
cheese with added 1 t tahini; 1 glass water or cup of 
milk based coffee. 
10:00 1C yogurt without fruit chunks, fruit puree; 1 
glass water 
19:30 Dinner: 2 t avocado or yogurt or repeat 
lunch, 1 glass water or ½ cup juice. 
 
13:00 Lunch: blenderized soup containing 50 
grams of cooked chicken/turkey, carrot, pumpkin, 
zucchini/carrot and potato with 1t oil. We 
recommend you eat this meal twice a day. 
21:00 (night): Yogurt 
 
Stage C-soft diet (not ground) 14-21 days after procedure: 
The transition to this phase is only if you manage well with stage B. 
Add all foods gradually and carefully in the following order: 
1. Meatballs (beef, chicken, turkey or fish) cooked and mashed with a fork; Bolognese; fish that is 
cooked or baked. Later add soft and well cooked chicken. 
2. Cooked noodles; later add well cooked rice. 
3. Cooked vegetables that are peeled and then mashed with a fork; fruit that is soft, peeled and 
without seeds. 
4. Bread or toast; unsweetened cereal. 
5. Fresh fruits and vegetables that are peeled, without seeds, and chopped (i.e., tomato, cucumber, 
soft peach/peart. 
6. It is recommended to add only one food a day. 
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Important rules for this stage: 
1. Continue chewing and eating slowly. 
2. Eat calmly and orderly. Do not get nervous or too hungry before meals. 
3. Each meal should be eaten in stages: First drinking, then eating raw or fresh vegetables, eating protein 
and finally eating carbohydrates. 
4. It is recommended to continue eating small volumes of food to avoid feeling pressure and nausea. If 
you experience these feelings, it is important to reduce the size of the meal. 
5. Allow 3-4 hours between meals. 
6. Keep on drinking 8-10 glasses of water throughout the day. 
7. Continue to take one multivitamin a day.  
 
Table 8: Example of daily routine-day 14-21 
07:00: 1C coffee with ½ C milk, sugar free 16:30 Snack: Fresh fruit or yogurt or slice of bread 
with 1T white cheese/tahini/hummus. 
Drink 1 glass water or 1C coffee with milk. 
08:00 Breakfast: 1 glass water; 1-2 vegetable with 
tuna/egg, 1 slice bread, 1 spoon avocado /tahini. 
19:30 Dinner 
Sugar free drinks; 1-2 fresh vegetables, 2T cottage 
cheese/1 slice of yellow cheese/2T tuna, 2-3 
crackers/slice of bread. 
10:00 snack: 1C yogurt without fruit; 1 glass water 21:00 Night: Yogurt and 2T Cornflakes. 
13:30 Lunch: Sugar free drinks, 2T cooked 
vegetable or vegetable soup or fresh vegetables; 1-
2 meatballs chicken, fish, meat (choose one-not 




3-4 weeks after the procedure: 
1. You can gradually return to normal eating with good chewing and eating slowly in small amounts at a 
time. 
2. At this time it’s important to start gradually exercise-like walking. Maintaining regular physical 
activity is important from now on will help you to achieve normal weight. 
o It’s recommended to exercise 150-200 (2.5-3 hrs.) minutes per week (for example: 34-50 
minutes for each workout 3-4 times). 
Important rules for the ENTIRE process (in addition to all the rules mentioned so far): 
▪ You should be in follow-up by the dietitian throughout the entire process. The purpose of the follow-
up is to support and assist you in solving problems that can occur after the procedure while allowing 
weight loss at your own rate.  
▪ It is very important to be attentive to your stomach-NOT to your head-and to pay attention to feelings 
of hunger and satiation. Stop eating when you feel full. 
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▪ Planning is the key in the process of weight loss. When you are away from home be sure to take a 
light meal such as a fruit, sandwich, energy bar, or yogurt. 
▪ Reduce or avoid eating foods that are high in fat, sugar and calories. These will prevent your desired 
weight (i.e., sweet drinks, milkshakes, ice cream, chocolate cookies, etc.) 
▪ Maintain a balanced and varied diet containing all food groups (vegetables, protein, carbohydrates, 
fat, vitamins and minerals). 
▪ Protein must be part of every meal. 
The subjects were strongly encourage to consider using a food tracker but were not required by the study. 
The choice of tool (writing, online tracking etc.) for tracking food intake was up to the subject’s personal 
preference. The Dietitian Intake Form, dietary instructions and physical exercise program forms were 
signed by the subject and the dietitian and sent to the company. At every follow-up visit forms were 
signed in the same way and sent to the company.  
RANDOMIZATION 
Subjects were randomly assigned to treatment or control groups with a 2:1 allocation as per computer 
generated randomization schedule. The statistician created this schedule and it was confidential. At the 
preimplantation visit the subjects were informed of the randomization. Those randomized to control 
visited with the dietitian to start their lifestyle modification and those randomized to the treatment group 
were set up for the procedure. 
WEEK 1 AND 2 FOLLOW UP VISITS 
Post balloon implantation, week 1 and week 2 follow-up visits were set up to help all the patients get 
guidance from the dietitian and the study team for symptoms management, diet compliance and address 
any concerns. The investigator of the study was the surgeon who performed the procedure. She/he tried to 
meet with the subjects at these visits especially if they were having serious issues including 
gastrointestinal pain, nausea, acid reflux, inability to drink enough fluids, discomfort in sleeping or other 
problems. All patients responded differently to balloon implantation so one-on-one counseling was part of 
the study design.  
The Dietitians met with patients individually at Week 1 and Week 2 visits (30 minute appointments) to 
evaluate the following: 
▪ Weight check: Weight was taken by the nursing staff that was blinded to the group 
randomization.  
▪ Fluid intake: to ensure ~10 cups fluids daily. 
▪ Food intake: Diet history was taken to check the status of the current diet. The goal was to ensure 
that they were gradually progressing from liquids to broth, juice, yogurt, milk, cottage cheese 
during the first week and to soft white cheese, cottage cheese, oatmeal (rice or corn flour), hard 
boiled eggs, tuna, vegetables/fruits purees without skin and seeds, fish/chicken (no skin) during 
the second week. 
▪ Protein intake: As expected all subjects added foods to their diet at their own pace and according 
to their own tolerance. If slow progression to the above stated foods was reported then it was an 
indication that the protein intake may not be sufficient. Suggestions were given to include protein 
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supplements such as shakes and powders. We explained the vital role of protein in recovery from 
the procedure.  
▪ Food tracking: We checked with them to verify if food tracking had been initiated. If so, inquired 
from them their average daily calories and protein intake. If not, gave encouragement to choose 
from the written, smart phone or online apps. It was reiterated that research findings have 
demonstrated more success with initial weight loss and keeping it off if the subjects tracked food 
intake.  
▪ Diet recommendations: Stage A (day 1-7) and Stage B (day 7-14) diet phases as per diet handout 
initially used at screen was reviewed again as needed. At screen visit there was information 
overload for the subjects therefore they welcomed the idea of repeating education in smaller 
segments.  
▪ Symptoms management: During the first few days the subjects were expected to have symptoms 
of constipation, stomach pain, nausea, weakness or reflux. We met during week 1 visit to help 
problem solve. If they were constipated we suggested increasing fluid intake and adding 1 
teaspoon of olive oil to foods. For reflux we advised separating out fluids and foods and avoid 
eating a couple of hours prior to bedtime. Factors responsible for weakness and low energy levels 
were inadequate diet therefore if tolerated we advised adding ample protein via foods or protein 
supplements. Consumption of essential fatty acids via foods such as tahini, hummus, avocado etc. 
helped balance the diet as well. A Multivitamin supplement daily is also beneficial in recovery. 
Stomachache, bloating or nausea indicated that possibly foods were progressed sooner than the 
stomach was ready or that the fluids were not spread out. In such a situation we suggested that the 
diet be stepped backwards until the symptoms are relieved and then adding one new food daily. If 
the new food caused these symptoms to discontinue it for a few days and tried again a few days 
later if desired. During week 2 visit the symptoms seemed to decrease in general which is 
expected. During week 2 stomach ache, bloating and reflux were the most prevalent symptoms. 
The causative factors for stomach ache and bloating at this stage were most likely due to not 
eating soft foods, not chewing foods properly, adding many new foods at the same time or eating 
too much quantity. We recommended that the food be mashed in the blender and starting with 
only 2 tablespoon of quantity consumed several times a day and gradually increasing the quantity 
as tolerated. Some patients experienced anxiety at this stage because on one hand they were 
looking forward to eating more foods but on the other hand they were scared of discomfort and 
jeopardizing weight loss. We reassured the subjects that following the recommended diet is safe. 
We reiterated that they would find it beneficial to track their food intake daily as it would give 
them a clear idea of the calories and protein being consumed.31 It would help them in planning 
and tweaking food intake and possibly reduce anxiety. We reminded the subjects that physical 
activity could be started at week 3. 
▪ Control group: The purpose of meeting with them was to ensure that they were on the same diet 
as the treatment group. Except for symptom management the visit with these groups was similar. 
They were asked if they were eating less, slowly and controlling hunger urges. The subjects in 
this group did not report any issues with following the recommended diet.   
The difference between these two visits was the administering of the General Practice Physical 




After the 2 weekly appointments monthly 30-minute follow-up visits were started. Following 
activities were covered during the appointments: 
▪ Weight check: Weight check by the nursing staff that were blinded to the group randomization. 
▪ Administered company specific follow-up form to collect the following information which was 
signed by the dietitian and the subject: 
o Is the subject eating less now than prior to beginning the study/balloon implantation? 
o Is the subject eating slower than prior to beginning the study/balloon implantation? 
o Is the subject able to control hunger urges better than prior to beginning the study/balloon 
implantation? 
o Did the subject fill out a food journal or diary? If yes their average caloric and protein 
intake. 
o Is the subject having difficulty with the current diet? If yes, explain. 
o Recommendations: Same diet/Change diet? (Circle one). List specific short-term goals? 
▪ Administered General Practice Physical Activity Questionnaire 
▪ We asked open-ended questions e.g., ‘share with me one thing that you think went well in the 
past few weeks’ in order to start the session with positivity. Usually they reported a new food 
they had tried or that they went out to eat and exercised control. We urged them to share more 
regarding this achievement(s) and how they manage to bring about the change. Some subjects 
reported that all was going well and there were no problems. For such a situation when they did 
not open up we asked them to think of one lifestyle thing that they felt they should/could 
improve. It could have been something as simple as adding one fruit daily or taking the stairs to 
the third floor office twice a day. In the process of administering the two forms stated above we 
were able to get a good idea of their problems and deficiencies in food intake and physical 
activity. In collaboration with the subject we guided them in setting realistic short-term SMART 
goals aimed at helping with their individual problems and struggles.  
▪ We covered a list of topics with the subjects at the follow-up visits. We let them choose a topic of 
interest at each visit. Over the holidays the subjects like to get input regarding modifying their 
favorite family recipes, strategies for eating at the family gatherings and how to disclose to others 
that were watching their diet.  Even if they responded that they already had good nutrition 
knowledge we attempted to cover a nutrition topic (healthy fats, whole grains, protein 
supplements, low simple sugars, sodium control, label reading, eating out, holiday cooking) with 
them to add to their knowledge.  
We used copies of the forms, bubble sheets with nutrition topics and our own notes from each visit to 
help with the follow-ups. For nutrition counseling we were restricted in using education materials to those 
approved by the company. We referred to MyPlate.com website for covering these topics. This was 
advantageous because the subjects did not have to deal with paper-work and also they could easily access 




CHALLENGES OF CONDUCTING THE STUDY 
▪ Educating both groups on the same diet: The control group had a difficult time following the liquid 
and the soft diet because they were capable of tolerating regular foods. Although, the subjects had 
signed a consent form to follow the diet irrespective of the group assignment they questioned it with 
the investigator. In response to this the study had an IRB modification after which the controls were 
advised to follow a liquid diet to begin with but then progress to a regular diet. They did not have to 
follow the diet progressions that the intervention group was supposed to follow. 
▪ Hurdles of compliance:  
o Availability of food: Subjects reported a variety of reasons for limited food choices in their 
environment including different food preferences from the rest of family members, expense, 
low usage and wastage of the produce, inadequate choices at work cafeteria and lack of time 
for shopping.  
o Willingness to try new foods: The treatment group was cautious during progression of the 
diet to the next level due to the fear of GI side effects and gaining weight. We guided them to 
add 1-2 new foods daily to help with ease of identifying any problem foods. Food tracking 
was suggested to get an idea of the caloric intake. In general those who disliked fruits and 
vegetables tried them for a short period and then went off them. Recipe ideas such as stir 
fries, salads, pasta replacement, soups, and smoothies were shared with them. 
o Cravings for sweets: Many of the subjects had a ‘sweet tooth’. Although post balloon 
implantation the appetite was decreased they continued to crave sweets at specific times of 
the day-most commonly afternoon. Strategies suggested included finding a distraction such as 
walking, reading and alternate food-fruit. Subjects reported finding satisfaction with a mini 
size candy, Jello, fruit etc. This compliance was followed by a period of week self-control 
(especially after the treatment group had recuperated) and indulgences with a big bag of 
candy or missed desserts. 
o Lack of time: In response to our suggestions/ideas ‘I don’t have the time’ was a frequent 
answer. Finding a balance between work, family life and a healthy lifestyle was a challenge. 
For physical activity we suggested incorporating daily lifestyle activities such as parking 
further away, taking stairs, walking breaks at work, family activities-walking, hiking, and 
biking. One subject came up with a unique idea to use a desk cycle. Some took turns with the 
spouse to work out at the gym. We suggested online free grocery shopping for those who 
struggled with time for grocery shopping. Subjects found this beneficial because it had the 
added advantage of avoiding impulse shopping. Many ideas/resources for helping build 
simple cooking skills were shared. We reiterated that planning ahead is the key to success. 
There were good examples of subjects preparing and portioning out main 
meat/poultry/seafood, vegetable/salad and snacks (nuts, cottage cheese, yogurt, fruit) food 
items over the weekend. A realistic approach to planning and management of meals and 
snacks was encourage therefore convenient, prepackage calorie controlled frozen meals for 
the hectic times were suggested instead of going through the fast food lane. High importance 
was given to family support and teamwork in working through these issues. Teaming up with 
significant other/children in meal planning and execution helped as it took some of the 
burden off the subject and also was instrumental in teaching children healthy eating habits via 
role-modelling.  
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o Self-control/Discipline: Compliance to the recommended healthy lifestyle was not consistent. 
The subjects reported periods of good self-control and compliance followed by (over) 
indulgence due to burnout and boredom. To overcome the ‘all or nothing’ phenomenon we 
suggested that the subjects try taking a day off a week from the diet as long as they mindfully 
followed the ‘hunger signals’ and ate when hungry, ate slowly and stopped when felt 
satisfied. Also, exercising ‘one bite rule’ was encourage if they badly missed a food. Over the 
holidays or routinely at work there are many treats in the environment that tested their will 
power and it was not easy to resist them. There were instances where the extended family 
members were opposed to the procedure and developed hostile behavior. The family and 
work gatherings centered around rich and heavy food. We gave suggestions to take foods that 
they could eat to the pot-luck or/and eat prior to the party.  
o Mental health and other health issues: Subjects who had diagnosis of depression and anxiety 
found it tough to stay driven to eat a healthy well balanced diet and be physically active. We 
continued to support them and suggested exploring activities and hobbies such as meditation, 
yoga, knitting, painting, book club etc. that they would find relaxing. We emphasized the 
important role of stress management. One subject tried basic yoga and found it helpful for 
relaxing after work. Strenuous physical activity was challenging for those who had joint pains 
therefore our advice was to try low impact exercises or10-15 minutes of walking 2-3 times 
daily as tolerated.  
o Portion control: The balloon implantation procedure was instrumental in limiting the quantity 
of food that could be consumed. For the control group it was more challenging. Our 
recommendations for both the groups were food measuring using a scale and measuring 
cups/spoons paired with food tracking using an online app or any other mode that worked for 
the subject. Food measuring may be necessary only for a couple of weeks until one is 
comfortable ‘eyeballing’ the foods. After that suggested keeping measuring equipment handy 
to use when in doubt. Subjects recorded food intake for a few days and then after that due to 
monotony, time commitment and complexity discontinued it. A few subjects opted to write 
food and behavior journals and found them helpful in identifying external factors during the 
day that triggered them to eat snacks. Physical Activity was easier to track for the subjects 
using smartphones, smart watch and Fit bit. 
▪ Research versus Clinical approach to counseling: Generally speaking, during weight loss counseling 
dietitians do not necessarily bring up the patient’s body weight in discussions. An effort is made to 
direct the conversations towards personalized healthy eating with the goal of weight loss. In research 
settings the visits are centered around the weight of the patient as per protocol guidelines. We convey 
to the patient the weight goal of the study upfront. During follow-up visits if there had been weight 
gain, we started by learning about the reasons and helped set goals in a very diplomatic manner. At 
the same time it is important for us to build rapport. This can be challenging.  
▪ Lack of psychologist: The study team did not have funding for the psychologist visit. Only one initial 
visit to evaluate the eligibility for behavior modification was included. We have done studies in the 
past with psychologist follow-up visits. Patients in those studies found the psychologist's support 
helpful in providing motivation for behavior modification, identifying obstacles, developing solutions 
etc. In this study we took on the role of cheerleading.  
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DISCUSSION AND FUTURE DIRECTION 
The study has many strengths as it included a randomized controlled study design. A multidisciplinary 
approach of a highly trained team including the investigator, study coordinators, RDs, and psychologist to 
help eligible subjects make individualized lifestyle changes was used. There were frequent one-on-one 
visits with both the groups to monitor the progress and provide individualized guidance in making 
changes. If additional care was needed for example if a subject in the intervention group called the study 
team post-operation to report that they were not keeping fluids down or had a stomach ache, an 
appointment was scheduled to help solve the problem if the phone call did not resolve the issue. Both the 
groups had equal numbers of visits and education content. The subjects were not given contact 
information of the registered dietitians for follow-up questions because this would have been a variable. 
They were encourage to keep a log of questions and bring them to their next appointment.  
The study had limitations. Self-monitoring of food intake and physical activity were optional and self-
reported by the subjects. Although the subjects were instructed to follow 1000-1200 calories after they 
had recovered from the procedure, data was not collected. This was a weakness in the design because 
tracking food intake from the subject's perspective is a time consuming task and takes a lot of dedication 
and motivation. Perhaps if it was required for the subjects to mail in food and exercise diaries we would 
have collected data for nutrient intake as well as diet and physical activity adherence. Group support was 
missing in this study. Due to patient confidentiality only one-on-one visits could be conducted. The 
subjects who in the past had tried commercial weight loss programs with group meetings reported that 
they would have benefited from interfacing with other subjects in this study. It would have given them an 
opportunity to share and compare their experiences, struggles and problem solving approaches. They 
asked if they could participate in other commercial programs for group support along with the study but 
this request was denied. For those who were active on the social media recommendations were made to 
use blogs selectively to connect with others who had similar weight loss procedures and experiences. 
In conclusion IGB is potentially an important tool to help manage obesity and its associated co-
morbidities. The adjustable IGB system is safe and effective. Even a small weight loss of 5-10% can 
improve health profile by lowering blood pressure, cholesterol levels and blood sugar levels. 9 It is a 
treatment option for those with whom previous interventions have been unsuccessful. Similar positive 
results were also reported by a retrospective study.32 In that study, results (demographic, medical and 
laboratory) from 2 academic centers and 5 private practices were compared for up to a year. The 
qualifying 202 adults had Reshape IGB inserted for 6 months along with lifestyle modification via diet 
and exercise for weight loss. At 1, 3, 6, 9 and 12 month time points mean %TBWL was 4.8 ± 2.4%, 8.8 ± 
4.3%, 11.4 ± 6.7%, 13.3 ± 7.8%, and 14.7 ± 11.8%, respectively. At 6 months data from 101 patients and 
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at 12 months data from 12 months was available which revealed that 60.4 % of the patients showed >10% 
TBWL and 55.4% had >25% EWL. Nausea (73.8% patients), vomiting (49% patients), and abdominal 
pain (25.2% patients) were the most common side effects reported. One patient needed surgical removal 
of the balloon as it migrated to the small intestine and resulted in obstruction. It was concluded that the 
Reshape Duo IGB is a safe and effective endoscopic method for weight loss when used for 6 months. 
Studies have also researched implantation of the IGB for a longer duration of time. Brooks et al. 
conducted a study with 73 consecutive patients at the Nucleus Healthcare Facility in Newport, Wales. In 
2011 and 2012 Spatz adjustable balloons were implanted for a year in 73 patients who were > 35 BMI. 
Mean weight loss of 21.6 kg, 19% weight loss and 45.7% EWL (excess weight loss) was reported from 
70 (49 at 12 months, 21 at <12 months) patients who finished the study. Three patients had problems with 
the catheter as it got stuck in the undiagnosed hiatal hernia or the duodenum and therefore the balloon had 
to be surgically removed. Failure rate in this study was 4.1%.They concluded that the balloon is an 
effective intervention for weight loss without the risk of mortality.30 
As a registered dietitian, my recommendations for future study are to include a combination of one-on-
one meetings and group nutrition classes for effective teaching, support groups and promote information 
sharing amongst the participants. I suggest having the subjects email the food intake online logs or 
bringing in written diaries for data collection. Similarly recommend giving to the participants a physical 
activity monitoring device and downloading the data. For both the groups it would have been interesting 
to have a pre and post randomization/procedure comparison of body composition via a dexa scan. The 
lifestyle changes and weight loss perhaps may have impacted body composition. However, it goes beyond 
the scope of a study to research all aspects of the main idea due to limited funding, complexity of the 
study design and also because the tests conducted should be related to the purpose of the study.  
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 Appendix A – DIETICIAN: Treatment Arm follow up visits 
 
Date:             Subject ID #  







Dietician – 1 & 2 week follow-up (after implant) 
 
● Subject Name  
● Subject Study # 
● Dietician Name  
● Weight 
● Visit Date  
 
1. Was the visit done?   Yes   /   No   
 














Dietician Signature, Date 
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Dietician – 4 week onwards (monthly visits) follow-up (after implant) 
 
● Subject Name  
● Subject Study # 
● Dietician Name  
● Weight 
● Visit Date  
 
4. Was the visit done?   Yes   /   No   
 
5. Is the subject eating less now than prior to balloon implantation?    Yes   /   No   
 
 
6. Is the subject eating slower than prior to balloon implantation?   Yes   /   No  
 
1. Is the subject able to control hunger urges better than prior to balloon implantation?    Yes   /   No 
 
2. Did the subject fill out a food journal or diary?  Yes   /   No 
 
3. Is the subject having difficulty with current diet?      Yes   /   No  



























Appendix C: Handout for exercise education 
 
Physical Exercise Program for the Spatz3 Adjustable Balloon Trial – for Balloon Patients and 
Control Patients 
Energy balance is the key for losing weight and is an important consideration in planning the proper 
physical activity. 
Research suggests that aerobic exercise of about 1000 kcal per week can result in weight loss of 4-6 lbs. 
/month. The physical activity should include a balance of resistance training as well as aerobic exercise 
which should be introduced gradually. 
Principles of planning physical activity  
● Losing weight is not the main goal, it is only a side effect.     
● The chosen activity should fit the characteristics of the patient (age, gender ,available time and 
place ,orthopedic and other health limitations ) 
●  Include exercises that can be done at home on a daily basis with simple equipment (or even with 
none) or in a gym or club that is nearby and is easy to access. 
● Start easy, with appropriate intensity and gradually increase both volume and intensity 
● Enjoy the activity – enjoyable activity is easier to maintain 
● Make time for the activity on a weekly schedule. 
Stage 1-Beginning physical activity (week #3 through 2 months) 
The main purpose of that stage is to be active and to raise body awareness 
 This stage starts for both treatment and control subjects at week #3   
Aerobic Exercise 
3-4 sessions per week of 15-25 min. of easy to moderate effort (HR=100-120 bpm) 
1. Walking outdoors or on treadmill  
2. Swimming 
3. Riding bicycles (outdoors, indoors, spinning or fitness bike) 
4. running  
Resistance training and core maintenance 
3-4 sessions per week of 15-20 min.1 set of 10-15 repetitions for each exercise. 
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Lower body (body weight resistance with no extra weight) 
 1. Half Squats      
 
 
● Heel raise 
● Lunges    
Upper body 
Using 3-8 lbs. dumbbells or low resistance rubber band in a standing position 
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● Biceps curls  








● Pushups in a diagonal position leaning on the wall or high table (low resistance) 




● Quadruped arm/leg diagonal raise  









Stage 2- enjoy the effort (months 3-5) 
The main purpose of that stage is to find and choose the right activity that suits the patient and try to 
enjoy more intensive activity 
Aerobic Exercise 
3-5 sessions per week of 20-35 min. of easy to moderate effort (50% maxHR=120-140 bpm) 
Resistance training and core maintenance 
3-4 sessions per week of 10-15 min. of 1 set of 12-15 repetitions for each exercise of the exercises shown 
on the previous stage 
Stretching 
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same routine as above 
Stage 3- physical activity as part of daily/weekly routine  
 (Months 6-8) 
Aerobic Exercise 
4-6 sessions per week of 25-40 min. of moderate effort (60% maxHR=130-150 bpm) 
Resistance training and core maintenance 
3-4 sessions per week of 20-25 min. of 1-2 sets of 12-20 repetitions for each exercise of the exercises 
shown on the previous stage 
Stretching 
Same routine as above 
 
 
 
